Literature DB >> 28923544

Modulation of oncogenic transcription factors by bioactive natural products in breast cancer.

Mohadeseh Hasanpourghadi1, Ashok Kumar Pandurangan1, Mohd Rais Mustafa2.   

Abstract

Carcinogenesis, a multi-step phenomenon, characterized by alterations at genetic level and affecting the main intracellular pathways controlling cell growth and development. There are growing number of evidences linking oncogenes to the induction of malignancies, especially breast cancer. Modulations of oncogenes lead to gain-of-function signals in the cells and contribute to the tumorigenic phenotype. These signals yield a large number of proteins that cause cell growth and inhibit apoptosis. Transcription factors such as STAT, p53, NF-κB, c-JUN and FOXM1, are proteins that are conserved among species, accumulate in the nucleus, bind to DNA and regulate the specific genes targets. Oncogenic transcription factors resulting from the mutation or overexpression following aberrant gene expression relay the signals in the nucleus and disrupt the transcription pattern. Activation of oncogenic transcription factors is associated with control of cell cycle, apoptosis, migration and cell differentiation. Among different cancer types, breast cancer is one of top ten cancers worldwide. There are different subtypes of breast cancer cell-lines such as non-aggressive MCF-7 and aggressive and metastatic MDA-MB-231 cells, which are identified with distinct molecular profile and different levels of oncogenic transcription factor. For instance, MDA-MB-231 carries mutated and overexpressed p53 with its abnormal, uncontrolled downstream signalling pathway that account for resistance to several anticancer drugs compared to MCF-7 cells with wild-type p53. Appropriate enough, inhibition of oncogenic transcription factors has become a potential target in discovery and development of anti-tumour drugs against breast cancer. Plants produce diverse amount of organic metabolites. Universally, these metabolites with biological activities are known as "natural products". The chemical structure and function of natural products have been studied since 1850s. Investigating these properties leaded to recognition of their molecular effects as anticancer drugs. Numerous natural products extracted from plants, fruits, mushrooms and mycelia, show potential inhibitory effects against several oncogenic transcription factors in breast cancer. Natural compounds that target oncogenic transcription factors have increased the number of candidate therapeutic agents. This review summarizes the current findings of natural products in targeting specific oncogenic transcription factors in breast cancer.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer drug; Breast cancer; MicroRNA; Natural products; Oncogenic transcription factors

Mesh:

Substances:

Year:  2017        PMID: 28923544     DOI: 10.1016/j.phrs.2017.09.009

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  9 in total

1.  The Novel Transcription Factor CREB3L4 Contributes to the Progression of Human Breast Carcinoma.

Authors:  Qian Pu; Li Lu; Ke Dong; Wen-Wen Geng; Yan-Rong Lv; Hai-Dong Gao
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-02-06       Impact factor: 2.673

Review 2.  Research Progress of Natural Small-Molecule Compounds Related to Tumor Differentiation.

Authors:  Xiaoli He; Yongkang Liao; Jing Liu; Shuming Sun
Journal:  Molecules       Date:  2022-03-25       Impact factor: 4.411

3.  Allyl Isothiocyanate Exhibits No Anticancer Activity in MDA-MB-231 Breast Cancer Cells.

Authors:  Md Abu Sayeed; Massimo Bracci; Veronica Ciarapica; Marco Malavolta; Mauro Provinciali; Ernesta Pieragostini; Simona Gaetani; Federica Monaco; Guendalina Lucarini; Venerando Rapisarda; Roberto Di Primio; Lory Santarelli
Journal:  Int J Mol Sci       Date:  2018-01-04       Impact factor: 5.923

4.  Anticancer efficiency of cycloartane triterpenoid derivatives isolated from Cimicifuga yunnanensis Hsiao on triple-negative breast cancer cells.

Authors:  Xiao Li; Wei Wang; Yi Fan; Yue Wei; Li-Qin Yu; Ji-Fu Wei; Yi-Fen Wang
Journal:  Cancer Manag Res       Date:  2018-12-06       Impact factor: 3.989

5.  miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib.

Authors:  Leisheng Wang; He En; Lei Yang; Yanbing Zhang; Baisheng Sun; Jianjiang Gao
Journal:  Onco Targets Ther       Date:  2019-08-21       Impact factor: 4.147

6.  Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).

Authors:  Jiachen Lu; Jianing Ding; Zhaoxia Liu; Tingtao Chen
Journal:  Int J Oncol       Date:  2022-01-04       Impact factor: 5.650

7.  Identification of Key Transcription Factors and Immune Infiltration Patterns Associated With Breast Cancer Prognosis Using WGCNA and Cox Regression Analysis.

Authors:  Xin Yin; Jiaxiang Liu; Xin Wang; Tianshu Yang; Gen Li; Yaxin Shang; Xu Teng; Hefen Yu; Shuang Wang; Wei Huang
Journal:  Front Oncol       Date:  2021-12-21       Impact factor: 6.244

8.  HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer.

Authors:  Li Li; Xin Guo; Xiaolei Zhou; Chunxiao Zhang; Yanyan Du; Tianming Li; Kaiqing Tong; Chongyue Zhu; Zijin Wang
Journal:  NPJ Breast Cancer       Date:  2022-01-13

9.  The microRNA miR-3174 Suppresses the Expression of ADAM15 and Inhibits the Proliferation of Patient-Derived Bladder Cancer Cells.

Authors:  Chunhu Yu; Ying Wang; Tiejun Liu; Kefu Sha; Zhaoxia Song; Mingjun Zhao; Xiaolin Wang
Journal:  Onco Targets Ther       Date:  2020-05-14       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.